Azaya Therapeutics, Inc. Appoints Michael T. Dwyer as President, Chief Executive Officer and Director
Mr. Dwyer brings to Azaya over 20 years of executive management experience in building, financing and managing emerging growth companies. He joins Azaya from Ingenix Pharmaceutical Services (i3 Research), a global contract research subsidiary of UnitedHealth Group, where he served as senior vice president and chief administrative officer. i3 Research has more than 1,000 employees in 20 countries with clinical trials being conducted in more than 45 countries.
“His wealth of experience will be invaluable in developing Azaya's pipeline of products around Azaya's innovative drug delivery technologies.”
"Mike Dwyer has an outstanding track record in building businesses in the biopharmaceutical industry and overseeing the development of new drugs," said John Kerr, the chairman of the board of Azaya. "His wealth of experience will be invaluable in developing Azaya's pipeline of products around Azaya's innovative drug delivery technologies."
Prior to i3 Research, Mr. Dwyer held a number of executive management positions with ILEX Oncology, Inc. in San Antonio. He served as the Chief Financial Officer and as the President and COO of ILEX's oncology contract research business. Mr. Dwyer was instrumental in the development and approval of Campath(R) (alemtuzumab).
Azaya is a biotechnology company that is developing the next generation of drug delivery technologies for the treatment of cancer. Its proprietary protein stabilizing liposomes (PSL) technology utilizes nanotechnology manufacturing processes to produce optimally sized liposomes for the targeted delivery of highly cytotoxic drugs.